Please sign in to follow a disease.

AN2 Therapeutics, Inc.

Clinical trials sponsored by AN2 Therapeutics, Inc., explained in plain language.

AN2 Therapeutics, Inc. ANTX NASDAQ

Clinical-stage biopharmaceutical company developing treatments for rare infectious diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1 Terminated 1

New drug AN2-502998 tested in healthy people for first time

Knowledge-focused Completed

This early-stage study tested a new oral drug called AN2-502998 in 72 healthy adults aged 18 to 55. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects and drug le…

Phase 1 • Sponsor: AN2 Therapeutics, Inc • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:25 UTC

AN2 Therapeutics, Inc.

New drug AN2-502998 tested in healthy people for first time